The jury hears the first words from Elizabeth Holmes, and they are damned very much. However, what he said was not from the witness stand - Holmes has not yet been called to testify. Instead, the attorney general aired interviews recorded by journalist Roger Barloff, who wrote a cover story while Holmes worked for Forbes. p>
In one clip, Barloff asked him how many experiments Tranos could do. "I think we can say more than 1,000," Holmes said. p>
In other excerpts, a jury heard Holmes tell the reporter, "The fact that we have one machine that can do any experiment." Secret.
The jury also heard Barloff ask Holmes if Theranos could essentially replace Quest Diagnostics, one of the nation's largest medical laboratories. Barloff indicated to Holmes that Quest could perform 600 experiments, including taking tissue samples.
More Theranos cost $2 million a week as investors expected it to be rosy. "So we can provide the data to clinicians for all the same tests," Holmes said after a short hesitation. When asked why he hesitated and did not say "replaced," he replied, "We process the samples in different ways, let's say so" and assured Barloff that the Theranos data was still "high quality."
Many of those statements were outright lies, or rather dancing around the truth. Erica Chung, a former lab associate, told the jury early in the trial: “In fact, Theranos could only perform a dozen experiments on Edison devices. The Edison Analyzer could only do more than a dozen experiments on Edison devices,” Cheung said when he took office in September. One type of test, one patient at a time." Holmes also shared medical reports with Parloff, displaying several drug company logos including Pfizer, Schering-Plow and GlaxoSmithKline. At the kiosk, Parloff confirmed that he was never told the reports were made. by Theranos and not approved by those companies.
Barloff also told the jury that Holmes never disclosed that most of their experiments were performed. It was done using third-party hardware, although he asked the question directly.
Article and Correction h2>
When Barloff's article was published in June 2014, part of Holmes shed. The package sent to attract investors is easy to understand why. In this article, Barloff describes the method of tapping Theranos' fingers - "For me , it was more like hitting, not punching" - and he listed a number of experiments the company could run with Lower cost than its competitors. "Tranos tests can be performed on a few drops of blood, or about 1/100 to 1/1,000 of what is normally required, which is a huge potential advantage for hospital patients or victims," Barloff wrote. Cancer, the elderly, infants, children, the obese, those on anticoagulants or simply anyone who hates taking blood. . The company even linked to it from its website. p>
However, in July 2015, during a Theranos demonstration at the law firm of a board member, Barloff noticed something strange. The company launched two devices, one to test for potassium and one to test for Ebola. "I was a little surprised that they needed two devices because I thought it could all be done," he told the court. Ask him to clarify the points raised in the article. In particular, he asked if Theranos could run several tests on its own devices by the end of 2014, the date mentioned in his article. "50, 60, maybe 70. We can get that number for you," Barloff told the court. Holmes told him.
Approximate Test Results
In the summer of 2015, at the time of the tests, Ellsworth was a retired dentist who was planning a two-year trip to Asia, where he was checked out to make sure he was willing to fly with his doctor, and Burns ordered a prostate cancer screening. He already had it, and recommended Theranos because the company's tests were cheaper than competitors, and the PSA count was high, at 26.1, a possible marker of prostate cancer. This time, the results were 1.71, which was similar to previous results before Tranos and did not indicate the presence of cancer. p>
Warning of the fetus. He did not trust any of these numbers and contacted Theranos. The director of the regional laboratory told him that the first result might have been a mistake. Burns said he was testing Elsworth for the third time and asked the district manager if Theranos would reimburse the costs, which he did.
Experiment 3 is back at its peak again - 22.9. Burns called Theranos and told the court that in the conversation, "You expressed mistrust of their experiences." Tranos was asked to pay for another test, this time via an intravenous lottery. The company agreed, and the result was normal - 0.95.
Inside Theranos, CEO Daniel Young and other employees discussed a series of unsuccessful emails in a lengthy email, which a jury noted was sent to Holmes. During questioning, Holmes' attorney asked Burns if he was aware of the error rate in medical diagnostic laboratories. Earlier, Burns noted that in his 30 years of medical practice, he has interpreted more than 10,000 prostate-specific antigen tests. He told the lawyer yes, labs can make mistakes. But it is "very rare."
In March 2016, nearly a year after Theranos released Blood of Swarth, the company sent a modified lab report to Burnes that invalidated the above numbers. PSA results, "should not be used with extreme caution." p>
Holmes claimed that Tranos could perform "more than 1,000 experiments" - 12 experiments
have been denied. T-Mobile confirmed the issue and said it is working on ...
New ambitious climate commitments force the International Energy Agency to reconsider its renewable energy outlookThe International Energy Agency says renewables must double by 2050 to tackle climate change.
Installed at an unprecedented speed. This trend...
The Federal Trade Commission (FTC) has sued Nvidia to retain Arm's status as the "Switzerland" of semiconductors.A lawsuit brought by a regulator threatens the largest chip merger in history.
Missouri government officials plan ...